Mirabegron And Ureteral Stent-related Pain (MAP) Trial

NCT04286152 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

142

Enrollment

OTHER

Sponsor class

Conditions

Nephrolithiasis

Interventions

DRUG: Mirabegron 50 MG
DRUG: Placebo oral tablet

Sponsor

Unity Health Toronto

Collaborators

[object Object]